Five experimental treatments have increased by 349% after positive cancer trial results

• Five Prime Therapeutics on Wednesday after the biotechnology company announced positive results for its Phase 2 trial evaluating bemerituzumab in stomach cancer. 349%.
• The five Prime Phase 2 Fight trials met all three primary endpoints of his study, including improvements to progress-free survival.
• “These results bring us one step closer to the first potential targeted treatment for advanced gastric cancer in a decade,” said Helen Collins, chief medical officer of the five prime ministers.
• Visit Business Insider’s homepage for more stories.

Shares of Five Prime Therapeutics rose more than 349% to $ 24.00 in Wednesday’s deal on potential progress in the treatment of stomach cancer.

The small-cap biotechnology company said Tuesday it has met all 3 pre-determined efficacy endpoints in front-line advanced gastric cancer and gastroesophageal junction cancer evaluation of its first-phase trial bemerituzumab.

Bimaretuzumab is a therapeutic antibody targeting FGFR2B + tumors found in about 30% of HR2-gastric cancers worldwide, the company said.

In the study, average progress-free survival improved from 7.4 months to 9.5 months. Average overall survival has not improved since 12.9 months, which means that patients in the trial are still alive and they have not yet determined what the average overall survival is.

read more: Biotech hunts for COVID-19 vaccines and has raised more than 1 1 billion this year by selling company stock. Here are the 27 leaders who have started the most.

In the trial, bemorituzumab was used in combination with chemotherapy, compared to the control group that received chemo therapy and placebo.

“These results bring us one step closer to the first potential targeted treatment for advanced gastric cancer in a decade,” said Helen Collins, chief medical officer of the five prime ministers.

Collins added that bemerituzumab may have therapeutic potential in other forms of cancer, including FGFR2B + squamous cell carcinoma, triple negative breast cancer, ovarian cancer, pancreatic cancer and pancreatic cancer.

Five Prime will evaluate all available data from its Phase 2 trial and work with investigators to present the results at the next medical conference.